GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (NAS:EGRX) » Definitions » Price-to-Owner-Earnings

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Price-to-Owner-Earnings : (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-04-29), Eagle Pharmaceuticals's share price is $4.05. Eagle Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Eagle Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

During the past 11 years, the highest Price-to-Owner-Earnings of Eagle Pharmaceuticals was 180.97. The lowest was 8.76. And the median was 24.89.


EGRX's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.82
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-29), Eagle Pharmaceuticals's share price is $4.05. Eagle Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.91. Therefore, Eagle Pharmaceuticals's PE Ratio for today is 4.45.

As of today (2024-04-29), Eagle Pharmaceuticals's share price is $4.05. Eagle Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $2.18. Therefore, Eagle Pharmaceuticals's PE Ratio without NRI for today is 1.86.

During the past 11 years, Eagle Pharmaceuticals's highest PE Ratio without NRI was 1400.00. The lowest was 1.85. And the median was 23.88.


Eagle Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Eagle Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Price-to-Owner-Earnings Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.91 31.67 65.96 - 17.04

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 172.21 - 17.04 54.98 -

Competitive Comparison of Eagle Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eagle Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's Price-to-Owner-Earnings falls into.



Eagle Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Eagle Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.05/-2.54
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eagle Pharmaceuticals  (NAS:EGRX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Eagle Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Eagle Pharmaceuticals (Eagle Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Executives
Scott Tarriff director, officer: President and CEO 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Richard A. Edlin director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Michael Shawn Moran officer: EVP, Chief Commercial Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF NJ 07677
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Brian Joseph Cahill officer: Chief Financial Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Judith Ng-cashin officer: Chief Medical Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Hudson Executive Capital Lp director C/O CADWALADER, WICKERSHAM & TAFT, LLP, 200 LIBERTY STREET, NEW YORK NY 10281
Hec Management Gp Llc director 1185 AVENUE OF THE AMERICAS, 32ND FLOOR, NEW YORK NY 10036
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Douglas L Braunstein director HUDSON EXECUTIVE CAPITAL LP, 570 LEXINGTON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Sander A Flaum director 630 PARK AVE, NEW YORK NY 10019
Pete A. Meyers officer: Chief Financial Officer C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE, MALVERN PA 19355
David Pernock director 405 EAGLEVIEW BOULEVARD, EXTON PA 19341
Proquest Investments Iv, L.p. 10 percent owner 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Steven L. Krill officer: Chief Scientific Officer C/O EAGLE PHARMCEUTICALS, INC., 50 TICE BLVD. SUITE 315, WOODCLIFF LAKE NJ 07677

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Headlines

From GuruFocus